Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04506801
Other study ID # 380-130/134-19-4
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 25, 2018
Est. completion date May 25, 2019

Study information

Verified date August 2020
Source University of Zagreb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main scope of the proposed research in the framework is to investigate the effect of probiotic bacteria Lactobacillus acidophilus LA3, Bifidobacterium animalis ssp. lactis BLC1 i Lactobacillus casei BGP93 on functional constipation and on the quality of life of the elderly in a nursing home. The experimental part will consists of double-blind, placebo-controlled clinical trial over 12 weeks.


Description:

During the first four weeks, the subjects were monitored primarily concerning bowel discharges and general health. After that initial four weeks, they are re-evaluated compliance with inclusion and exclusion criteria. Participants were allocated to the double-blind section of the trial (12 weeks), using o computer-generated to a placebo group or in the probiotic group in the form of a liquid oral formulation once a day. On first day of intervention participants provide a blood sample. All investigators, participants and study personnel were blinded to the order of randomization. Participants were told to consume 9 drops of study probiotics once a day for next 12-week intervention. On last day of intervention, participants provide a blood sample. The last four weeks of the double-blind section (week 9-12) participants an evaluation period in which the respondents were evaluated for the outcomes of the study. After completing the double-blind study, the participants were followed for an additional four weeks. Inclusive / Excluded criteria are evaluated on two occasions, at the time of inclusion in the 4-week introductory section and its end.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date May 25, 2019
Est. primary completion date March 25, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria:

- age 65 years or more

- signed informed consent for study participation

- functional constipation defined by Rome IV criteria

- ability to understand the procedure

Exclusion Criteria:

- suspicion of obstructive ileus or previous obstructive ileus

- suspected or confirmed diagnosis: irritable colon syndrome, ulcerative colitis, Crohn's disease, malignant digestive tract disease

- diarrhoea of any cause within the last month

- acute infectious disease within the last month excluding people who use antibiotics

- persons who have opioid analgesics in pharmacotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probalans senior
Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
Other:
Placebo
Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention

Locations

Country Name City State
Croatia Katarina Fehir Šola Bjelovar

Sponsors (1)

Lead Sponsor Collaborator
Katarina Fehir Šola

Country where clinical trial is conducted

Croatia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in stool frequency in patients who use probiotics The proportion of subjects who meet the criterion of "normal bowel movement" according to the Roman IV criteria, at least 3 times a week to no more than 3 times a day. This proportion will be determined for each of the 4 evaluation weeks and will be analyzed as a time-averaged proportion. The proportion will be estimated on the basis of the subjects' diaries in which, by days, with indicated dates, the subjects will record each bowel emptying. Investigators would inform the evidence base with regards to the multi-strained probiotic efficacy in treating constipation among the elderly. 12 weeks
Secondary Change in hs-CRP at the blood of a patient who uses probiotics determined by immunoturbidimetric method The secondary outcome is to investigate the effect of selected probiotic strains on the concentration of the marker of inflammation, hs c-reactive protein (hs-CRP) in the serum of the subjects. hs-CRP will be determined by the immunoturbidimetric method. Investigators wanted to study the effect of this multi-strained probiotic on clinical and laboratory parameters. Blood was collected before the probiotic intervention and after 12 weeks. 12 weeks
Secondary Change in glucose parameters of a patient who use probiotics determined by standard laboratory methods Values of laboratory indicators - glucose metabolism will be monitored. Investigators wanted to study the effect of this multi-strained probiotic on glucose parameters. Blood was collected like in Outcome2, before the intervention and after the intervention. 12 weeks
Secondary Change in blood parameters- triglycerides of a patient who use probiotics determined by standard laboratory methods. Values of laboratory indicators of lipid metabolism - triglycerides will be monitored. Blood was collected before and after the intervention. Investigators wanted to study the effect of multi-strain probiotics on triglycerides. 12 weeks
Secondary Change in blood parameter- total cholesterol of a patient determined by standard laboratory methods Investigator monitoring change of laboratory indicators of total cholesterol in beginning and at the end of the intervention with multi-strain probiotics. 12 weeks
Secondary Change in HDL cholesterol in blood parameters of a patient who use probiotics determined by standard laboratory methods Values of laboratory indicators of HDL (high density lipoprotein) will be monitoring during the intervention. Blood samples were collected before and after the intervention. 12 weeks
Secondary Change in LDL cholesterol at the blood of patients who use probiotics determined by standard laboratory methods Investigator monitoring change of laboratory indicators of LDL(low density lipoprotein), before study and at the end of the intervention. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04620161 - A Proof of Concept Study of Pradigastat in Patients With Functional Constipation Phase 2
Active, not recruiting NCT02361749 - Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation Phase 4
Completed NCT03054805 - The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation Phase 4
Not yet recruiting NCT01913665 - The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation N/A
Completed NCT01348152 - Effect of TU-100 in Patients With Functional Constipation Phase 2
Completed NCT01622972 - Mode of Action of Moviprep Phase 4
Completed NCT01212146 - Probiotic-enriched Artichoke in Functional Constipation N/A
Completed NCT04231162 - Effect of an 8-week Bifidobacterium Lactis HN019 Supplementation on Functional Constipation N/A
Not yet recruiting NCT03639142 - Dried Plums (Prunes) vs. Polyethylene Glycol 4000 for Treatment of Functional Constipation in Children Phase 3
Recruiting NCT04918329 - Functional Digestive Disorders Observatory
Completed NCT02592200 - Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women N/A
Completed NCT03707002 - Effect of scFOS on Increase in Stool Frequency in Constipated People N/A
Recruiting NCT06083311 - The Efficacy of a Probiotic for Functional Constipation (FC) N/A
Completed NCT04110145 - Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation Phase 2
Recruiting NCT06196073 - Visceral Osteopathy in Functional Constipation N/A
Active, not recruiting NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Completed NCT02359396 - A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics Phase 1
Completed NCT01847950 - Effects of scFOS on Stool Frequency in People With Functionnal Constipation N/A
Recruiting NCT01274793 - Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy Phase 1
Enrolling by invitation NCT04166058 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase 3